Comparative  ||| S:0 E:12 ||| JJ
risk  ||| S:12 E:17 ||| NN
of  ||| S:17 E:20 ||| IN
microalbuminuria  ||| S:20 E:37 ||| NN
and  ||| S:37 E:41 ||| CC
proteinuria  ||| S:41 E:53 ||| NN
in  ||| S:53 E:56 ||| IN
UK  ||| S:56 E:59 ||| NNP
residents  ||| S:59 E:69 ||| NNS
of  ||| S:69 E:72 ||| IN
south  ||| S:72 E:78 ||| RB
Asian  ||| S:78 E:84 ||| JJ
and  ||| S:84 E:88 ||| CC
white  ||| S:88 E:94 ||| JJ
European  ||| S:94 E:103 ||| JJ
ethnic  ||| S:103 E:110 ||| JJ
background  ||| S:110 E:121 ||| NN
with  ||| S:121 E:126 ||| IN
type  ||| S:126 E:131 ||| NN
2  ||| S:131 E:133 ||| CD
diabetes ||| S:133 E:141 ||| NN
:  ||| S:141 E:143 ||| :
a  ||| S:143 E:145 ||| DT
report  ||| S:145 E:152 ||| NN
from  ||| S:152 E:157 ||| IN
UKADS  ||| S:157 E:163 ||| NNP
This  ||| S:163 E:168 ||| DT
study  ||| S:168 E:174 ||| NN
investigated  ||| S:174 E:187 ||| NNS
and  ||| S:187 E:191 ||| CC
compared  ||| S:191 E:200 ||| VBN
the  ||| S:200 E:204 ||| DT
prevalence  ||| S:204 E:215 ||| NN
of  ||| S:215 E:218 ||| IN
microalbuminuria  ||| S:218 E:235 ||| NN
and  ||| S:235 E:239 ||| CC
overt  ||| S:239 E:245 ||| JJ
proteinuria  ||| S:245 E:257 ||| NN
and  ||| S:257 E:261 ||| CC
their  ||| S:261 E:267 ||| PRP$
determinants  ||| S:267 E:280 ||| NN
in  ||| S:280 E:283 ||| IN
a  ||| S:283 E:285 ||| DT
cohort  ||| S:285 E:292 ||| NN
of  ||| S:292 E:295 ||| IN
UK  ||| S:295 E:298 ||| NNP
resident  ||| S:298 E:307 ||| NN
patients  ||| S:307 E:316 ||| NNS
of  ||| S:316 E:319 ||| IN
white  ||| S:319 E:325 ||| JJ
European  ||| S:325 E:334 ||| JJ
or  ||| S:334 E:337 ||| CC
south  ||| S:337 E:343 ||| RB
Asian  ||| S:343 E:349 ||| JJ
ethnicity  ||| S:349 E:359 ||| NN
with  ||| S:359 E:364 ||| IN
type  ||| S:364 E:369 ||| NN
2  ||| S:369 E:371 ||| CD
diabetes  ||| S:371 E:380 ||| NN
mellitus ||| S:380 E:388 ||| NN
.  ||| S:388 E:390 ||| .
A  ||| S:390 E:392 ||| DT
total  ||| S:392 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
1978  ||| S:401 E:406 ||| CD
patients ||| S:406 E:414 ||| NNS
,  ||| S:414 E:416 ||| ,
comprising  ||| S:416 E:427 ||| VBG
1486  ||| S:427 E:432 ||| CD
of  ||| S:432 E:435 ||| IN
south  ||| S:435 E:441 ||| RB
Asian  ||| S:441 E:447 ||| JJ
and  ||| S:447 E:451 ||| CC
492  ||| S:451 E:455 ||| CD
of  ||| S:455 E:458 ||| IN
white  ||| S:458 E:464 ||| JJ
European  ||| S:464 E:473 ||| JJ
ethnicity ||| S:473 E:482 ||| NN
,  ||| S:482 E:484 ||| ,
in  ||| S:484 E:487 ||| IN
25  ||| S:487 E:490 ||| CD
general  ||| S:490 E:498 ||| JJ
practices  ||| S:498 E:508 ||| NNS
in  ||| S:508 E:511 ||| IN
Coventry  ||| S:511 E:520 ||| NNP
and  ||| S:520 E:524 ||| CC
Birmingham  ||| S:524 E:535 ||| NNP
inner  ||| S:535 E:541 ||| JJ
city  ||| S:541 E:546 ||| NN
areas  ||| S:546 E:552 ||| NNS
in  ||| S:552 E:555 ||| IN
England  ||| S:555 E:563 ||| NNP
were  ||| S:563 E:568 ||| VBD
studied  ||| S:568 E:576 ||| VBN
in  ||| S:576 E:579 ||| IN
a  ||| S:579 E:581 ||| DT
cross-sectional  ||| S:581 E:597 ||| JJ
study ||| S:597 E:602 ||| NN
.  ||| S:602 E:604 ||| .
Demographic  ||| S:604 E:616 ||| NNP
and  ||| S:616 E:620 ||| CC
risk  ||| S:620 E:625 ||| NN
factor  ||| S:625 E:632 ||| NN
data  ||| S:632 E:637 ||| NNS
were  ||| S:637 E:642 ||| VBD
collected  ||| S:642 E:652 ||| VBN
and  ||| S:652 E:656 ||| CC
presence  ||| S:656 E:665 ||| NN
of  ||| S:665 E:668 ||| IN
microalbuminuria  ||| S:668 E:685 ||| NN
and  ||| S:685 E:689 ||| CC
overt  ||| S:689 E:695 ||| JJ
proteinuria  ||| S:695 E:707 ||| NN
assessed ||| S:707 E:715 ||| VBD
.  ||| S:715 E:717 ||| .
ISRCTN  ||| S:717 E:724 ||| NNP
38297969 ||| S:724 E:732 ||| CD
.  ||| S:732 E:734 ||| .
Prevalences  ||| S:734 E:746 ||| NNP
of  ||| S:746 E:749 ||| IN
microalbuminuria  ||| S:749 E:766 ||| NN
and  ||| S:766 E:770 ||| CC
overt  ||| S:770 E:776 ||| JJ
proteinuria ||| S:776 E:787 ||| NN
.  ||| S:787 E:789 ||| .
Urinary  ||| S:789 E:797 ||| JJ
albumin ||| S:797 E:804 ||| NN
: ||| S:804 E:805 ||| :
creatinine  ||| S:805 E:816 ||| JJ
measurements  ||| S:816 E:829 ||| NNS
were  ||| S:829 E:834 ||| VBD
available  ||| S:834 E:844 ||| JJ
for  ||| S:844 E:848 ||| IN
1852  ||| S:848 E:853 ||| CD
( ||| S:853 E:854 ||| -LRB-
94 ||| S:854 E:856 ||| CD
% ||| S:856 E:857 ||| NN
)  ||| S:857 E:859 ||| -RRB-
patients ||| S:859 E:867 ||| NNS
.  ||| S:867 E:869 ||| .
The  ||| S:869 E:873 ||| DT
south  ||| S:873 E:879 ||| JJ
Asian  ||| S:879 E:885 ||| JJ
group  ||| S:885 E:891 ||| NN
had  ||| S:891 E:895 ||| VBD
a  ||| S:895 E:897 ||| DT
lower  ||| S:897 E:903 ||| JJR
prevalence  ||| S:903 E:914 ||| NN
of  ||| S:914 E:917 ||| IN
microalbuminuria ||| S:917 E:933 ||| NN
,  ||| S:933 E:935 ||| ,
19 ||| S:935 E:937 ||| CD
%  ||| S:937 E:939 ||| NN
vs.  ||| S:939 E:943 ||| IN
23 ||| S:943 E:945 ||| CD
%  ||| S:945 E:947 ||| NN
and  ||| S:947 E:951 ||| CC
a  ||| S:951 E:953 ||| DT
higher  ||| S:953 E:960 ||| JJR
prevalence  ||| S:960 E:971 ||| NN
of  ||| S:971 E:974 ||| IN
overt  ||| S:974 E:980 ||| JJ
proteinuria ||| S:980 E:991 ||| NN
,  ||| S:991 E:993 ||| ,
8 ||| S:993 E:994 ||| CD
%  ||| S:994 E:996 ||| NN
vs.  ||| S:996 E:1000 ||| IN
3 ||| S:1000 E:1001 ||| CD
% ||| S:1001 E:1002 ||| NN
,  ||| S:1002 E:1004 ||| ,
χ ||| S:1004 E:1005 ||| NNS
( ||| S:1005 E:1006 ||| -LRB-
2 ||| S:1006 E:1007 ||| CD
)  ||| S:1007 E:1009 ||| CD
=  ||| S:1009 E:1011 ||| SYM
15.85 ||| S:1011 E:1016 ||| CD
,  ||| S:1016 E:1018 ||| ,
2df ||| S:1018 E:1021 ||| NNP
,  ||| S:1021 E:1023 ||| ,
P  ||| S:1023 E:1025 ||| NN
=  ||| S:1025 E:1027 ||| SYM
0.0004 ||| S:1027 E:1033 ||| CD
.  ||| S:1033 E:1035 ||| .
In  ||| S:1035 E:1038 ||| IN
multiple  ||| S:1038 E:1047 ||| JJ
logistic  ||| S:1047 E:1056 ||| JJ
regression  ||| S:1056 E:1067 ||| JJ
models ||| S:1067 E:1073 ||| NNS
,  ||| S:1073 E:1075 ||| ,
adjusted  ||| S:1075 E:1084 ||| VBN
for  ||| S:1084 E:1088 ||| IN
confounding  ||| S:1088 E:1100 ||| JJ
factors ||| S:1100 E:1107 ||| NNS
,  ||| S:1107 E:1109 ||| ,
significantly  ||| S:1109 E:1123 ||| RB
increased  ||| S:1123 E:1133 ||| VBN
risk  ||| S:1133 E:1138 ||| NN
for  ||| S:1138 E:1142 ||| IN
the  ||| S:1142 E:1146 ||| DT
south  ||| S:1146 E:1152 ||| JJ
Asian  ||| S:1152 E:1158 ||| JJ
vs.  ||| S:1158 E:1162 ||| IN
white  ||| S:1162 E:1168 ||| JJ
European  ||| S:1168 E:1177 ||| JJ
patients  ||| S:1177 E:1186 ||| NNS
for  ||| S:1186 E:1190 ||| IN
overt  ||| S:1190 E:1196 ||| JJ
proteinuria  ||| S:1196 E:1208 ||| NN
was  ||| S:1208 E:1212 ||| VBD
shown ||| S:1212 E:1217 ||| VBN
;  ||| S:1217 E:1219 ||| :
OR  ||| S:1219 E:1222 ||| NNP
( ||| S:1222 E:1223 ||| -LRB-
95 ||| S:1223 E:1225 ||| CD
%  ||| S:1225 E:1227 ||| NN
CI ||| S:1227 E:1229 ||| NNP
)  ||| S:1229 E:1231 ||| -RRB-
2.17  ||| S:1231 E:1236 ||| CD
( ||| S:1236 E:1237 ||| -LRB-
1.05 ||| S:1237 E:1241 ||| CD
,  ||| S:1241 E:1243 ||| ,
4.49 ||| S:1243 E:1247 ||| CD
) ||| S:1247 E:1248 ||| -RRB-
,  ||| S:1248 E:1250 ||| ,
P  ||| S:1250 E:1252 ||| NN
=  ||| S:1252 E:1254 ||| SYM
0.0365 ||| S:1254 E:1260 ||| CD
.  ||| S:1260 E:1262 ||| .
For  ||| S:1262 E:1266 ||| IN
microalbuminuria ||| S:1266 E:1282 ||| NN
,  ||| S:1282 E:1284 ||| ,
an  ||| S:1284 E:1287 ||| DT
interaction  ||| S:1287 E:1299 ||| JJ
effect  ||| S:1299 E:1306 ||| NN
for  ||| S:1306 E:1310 ||| IN
ethnicity  ||| S:1310 E:1320 ||| NN
and  ||| S:1320 E:1324 ||| CC
duration  ||| S:1324 E:1333 ||| NN
of  ||| S:1333 E:1336 ||| IN
diabetes  ||| S:1336 E:1345 ||| NN
suggested  ||| S:1345 E:1355 ||| VBD
that  ||| S:1355 E:1360 ||| DT
risk  ||| S:1360 E:1365 ||| NN
for  ||| S:1365 E:1369 ||| IN
south  ||| S:1369 E:1375 ||| RB
Asian  ||| S:1375 E:1381 ||| JJ
patients  ||| S:1381 E:1390 ||| NNS
was  ||| S:1390 E:1394 ||| VBD
lower  ||| S:1394 E:1400 ||| JJR
in  ||| S:1400 E:1403 ||| IN
early  ||| S:1403 E:1409 ||| JJ
years  ||| S:1409 E:1415 ||| NNS
following  ||| S:1415 E:1425 ||| VBG
diagnosis ||| S:1425 E:1434 ||| NN
;  ||| S:1434 E:1436 ||| :
OR  ||| S:1436 E:1439 ||| NNP
for  ||| S:1439 E:1443 ||| IN
SA  ||| S:1443 E:1446 ||| NNP
vs.  ||| S:1446 E:1450 ||| FW
WH  ||| S:1450 E:1453 ||| NNP
at  ||| S:1453 E:1456 ||| IN
durations  ||| S:1456 E:1466 ||| CD
0  ||| S:1466 E:1468 ||| CD
and  ||| S:1468 E:1472 ||| CC
1  ||| S:1472 E:1474 ||| CD
year  ||| S:1474 E:1479 ||| NN
were  ||| S:1479 E:1484 ||| VBD
0.56  ||| S:1484 E:1489 ||| CD
( ||| S:1489 E:1490 ||| -LRB-
0.37 ||| S:1490 E:1494 ||| CD
,  ||| S:1494 E:1496 ||| ,
0.86 ||| S:1496 E:1500 ||| CD
)  ||| S:1500 E:1502 ||| -RRB-
and  ||| S:1502 E:1506 ||| CC
0.59  ||| S:1506 E:1511 ||| CD
( ||| S:1511 E:1512 ||| -LRB-
0.39 ||| S:1512 E:1516 ||| CD
,  ||| S:1516 E:1518 ||| ,
0.89 ||| S:1518 E:1522 ||| CD
)  ||| S:1522 E:1524 ||| -RRB-
respectively ||| S:1524 E:1536 ||| RB
.  ||| S:1536 E:1538 ||| .
After  ||| S:1538 E:1544 ||| IN
20  ||| S:1544 E:1547 ||| CD
years ||| S:1547 E:1552 ||| NNS
'  ||| S:1552 E:1554 ||| POS
duration ||| S:1554 E:1562 ||| NN
,  ||| S:1562 E:1564 ||| ,
OR  ||| S:1564 E:1567 ||| NNP
=  ||| S:1567 E:1569 ||| SYM
1.40  ||| S:1569 E:1574 ||| CD
( ||| S:1574 E:1575 ||| -LRB-
0.63 ||| S:1575 E:1579 ||| CD
,  ||| S:1579 E:1581 ||| ,
3.08 ||| S:1581 E:1585 ||| CD
) ||| S:1585 E:1586 ||| -RRB-
.  ||| S:1586 E:1588 ||| .
Comparability  ||| S:1588 E:1602 ||| NNP
of  ||| S:1602 E:1605 ||| IN
ethnicity  ||| S:1605 E:1615 ||| JJ
defined  ||| S:1615 E:1623 ||| JJ
groups ||| S:1623 E:1629 ||| NNS
;  ||| S:1629 E:1631 ||| :
statistical  ||| S:1631 E:1643 ||| JJ
methods  ||| S:1643 E:1651 ||| NNS
controlled  ||| S:1651 E:1662 ||| VBN
for  ||| S:1662 E:1666 ||| IN
differences  ||| S:1666 E:1678 ||| NNS
between  ||| S:1678 E:1686 ||| IN
groups ||| S:1686 E:1692 ||| NNS
,  ||| S:1692 E:1694 ||| ,
but  ||| S:1694 E:1698 ||| CC
residual  ||| S:1698 E:1707 ||| JJ
confounding  ||| S:1707 E:1719 ||| NN
may  ||| S:1719 E:1723 ||| MD
remain ||| S:1723 E:1729 ||| VB
.  ||| S:1729 E:1731 ||| .
Analyses  ||| S:1731 E:1740 ||| NNS
are  ||| S:1740 E:1744 ||| VBP
based  ||| S:1744 E:1750 ||| VBN
on  ||| S:1750 E:1753 ||| IN
a  ||| S:1753 E:1755 ||| DT
single  ||| S:1755 E:1762 ||| JJ
measure  ||| S:1762 E:1770 ||| NN
of  ||| S:1770 E:1773 ||| IN
albumin ||| S:1773 E:1780 ||| NNS
: ||| S:1780 E:1781 ||| :
creatinine  ||| S:1781 E:1792 ||| JJ
ratio ||| S:1792 E:1797 ||| NN
.  ||| S:1797 E:1799 ||| .
There  ||| S:1799 E:1805 ||| EX
were  ||| S:1805 E:1810 ||| VBD
significant  ||| S:1810 E:1822 ||| JJ
differences  ||| S:1822 E:1834 ||| NNS
between  ||| S:1834 E:1842 ||| IN
ethnicity  ||| S:1842 E:1852 ||| JJ
groups  ||| S:1852 E:1859 ||| NNS
in  ||| S:1859 E:1862 ||| IN
risk  ||| S:1862 E:1867 ||| NN
factor  ||| S:1867 E:1874 ||| NN
profiles  ||| S:1874 E:1883 ||| NNS
and  ||| S:1883 E:1887 ||| CC
microalbuminuria  ||| S:1887 E:1904 ||| NNS
and  ||| S:1904 E:1908 ||| CC
overt  ||| S:1908 E:1914 ||| JJ
proteinuria  ||| S:1914 E:1926 ||| JJ
outcomes ||| S:1926 E:1934 ||| NNS
.  ||| S:1934 E:1936 ||| .
Whilst  ||| S:1936 E:1943 ||| NNP
south  ||| S:1943 E:1949 ||| RB
Asian  ||| S:1949 E:1955 ||| JJ
patients  ||| S:1955 E:1964 ||| NNS
had  ||| S:1964 E:1968 ||| VBD
no  ||| S:1968 E:1971 ||| DT
excess  ||| S:1971 E:1978 ||| JJ
risk  ||| S:1978 E:1983 ||| NN
of  ||| S:1983 E:1986 ||| IN
microalbuminuria ||| S:1986 E:2002 ||| NN
,  ||| S:2002 E:2004 ||| ,
the  ||| S:2004 E:2008 ||| DT
risk  ||| S:2008 E:2013 ||| NN
of  ||| S:2013 E:2016 ||| IN
overt  ||| S:2016 E:2022 ||| JJ
proteinuria  ||| S:2022 E:2034 ||| NN
was  ||| S:2034 E:2038 ||| VBD
elevated  ||| S:2038 E:2047 ||| VBN
significantly ||| S:2047 E:2060 ||| RB
,  ||| S:2060 E:2062 ||| ,
which  ||| S:2062 E:2068 ||| WDT
might  ||| S:2068 E:2074 ||| MD
be  ||| S:2074 E:2077 ||| VB
explained  ||| S:2077 E:2087 ||| VBN
by  ||| S:2087 E:2090 ||| IN
faster  ||| S:2090 E:2097 ||| JJR
progression  ||| S:2097 E:2109 ||| NN
of  ||| S:2109 E:2112 ||| IN
renal  ||| S:2112 E:2118 ||| JJ
dysfunction  ||| S:2118 E:2130 ||| NN
in  ||| S:2130 E:2133 ||| IN
patients  ||| S:2133 E:2142 ||| NNS
of  ||| S:2142 E:2145 ||| IN
south  ||| S:2145 E:2151 ||| RB
Asian  ||| S:2151 E:2157 ||| JJ
ethnicity ||| S:2157 E:2166 ||| NN
.  ||| S:2166 E:2168 ||| .
